Signatera™ — Knowing Early Can Make a Difference

In collaboration with Natera and Lifelabs, Colorectal Cancer Canada (CCC) hosted an Information Webinar for healthcare professionals regarding the Canadian launch of Signatera™, on February 13th 2023.

Signatera™ is a highly sensitive molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA) custom designed for each patient. It will offer patients a unique and personalized diagnostic solution that can offer support for more precise clinical decisions which can be used to accurately detect and quantify residual tumour burden after treatment has started and/or completed.

This webinar provides information on the Signatera™ test, case studies and experiences from medical oncologists in the US and Canada. The panel discussion was followed by a Q&A session from the live audience.

The panel was moderated by CCC’s, Barry Stein, as he was joined by esteemed panel members:
Dr. Jonathon Loree, Medical Oncologist, BC Cancer
Dr. Adham Jurdi, Medical Director, Oncology at Natera
Dr. Hagen F. Kennecke, Medical Director of GI Oncology, Portland Providence Cancer Center

Видео Signatera™ — Knowing Early Can Make a Difference канала Colorectal Cancer Canada